$2.36
19.73% yesterday
NYSE, Nov 15, 10:05 pm CET
ISIN
US36870H1032
Symbol
GNLX
Sector
Industry

Genelux Stock price

$2.36
-0.83 26.02% 1M
-1.28 35.16% 6M
-11.65 83.15% YTD
-11.12 82.49% 1Y
-3.64 60.67% 3Y
-3.64 60.67% 5Y
-3.64 60.67% 10Y
NYSE, Closing price Fri, Nov 15 2024
-0.58 19.73%
ISIN
US36870H1032
Symbol
GNLX
Sector
Industry

Key metrics

Market capitalization $81.50m
Enterprise Value $49.48m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 4,948.00
P/S ratio (TTM) P/S ratio 8,150.00
P/B ratio (TTM) P/B ratio 2.46
Revenue growth (TTM) Revenue growth -96.64%
Revenue (TTM) Revenue $10.00k
EBIT (operating result TTM) EBIT $-28.95m
Cash position $33.64m
EPS (TTM) EPS $-0.95
P/E forward negative
P/S forward 21,152.08
EV/Sales forward 14,604.17
Short interest 4.92%
Show more

Is Genelux a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Genelux Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Genelux forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Genelux forecast:

Buy
100%

Financial data from Genelux

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.01 0.01
96% 96%
100%
- Direct Costs - -
-
-
-0.87 -0.87
6% 6%
-8,700%
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 17 17
50% 50%
166,400%
- -
-
-
- Depreciation and Amortization 0.88 0.88
17% 17%
8,800%
EBIT (Operating Income) EBIT -29 -29
43% 43%
-289,490%
Net Profit -28 -28
11% 11%
-276,600%

In millions USD.

Don't miss a Thing! We will send you all news about Genelux directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genelux Stock News

Neutral
GlobeNewsWire
9 days ago
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference, taking pl...
Neutral
Seeking Alpha
15 days ago
Topline results from phase 3 OnPrime/GOG-3076 study using Olvi-Vec for the treatment of patients with platinum-resistant recurrent ovarian cancer, are expected in the 2nd half of 2025. Interim data from phase 2 U.S. trial using Olvi-Vec for the treatment of patients with non-small cell lung cancer is expected mid-2025. Interim results from phase 1b/2 China study, using Olvi-Vec for the treatmen...
Neutral
GlobeNewsWire
24 days ago
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer –
More Genelux News

Company Profile

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Head office United States
CEO Thomas Zindrick
Employees 23
Founded 2001
Website www.genelux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today